What Everyone Needs To Know About Polymorphs

If you’re involved in late-stage drug discovery, API manufacturing, drug product formulation, clinical material production, or final dosage form manufacturing, a foundational understanding of solid form behavior can save significant time, cost, and complexity throughout development. Among these considerations, polymorphism stands out as one of the most important — and often misunderstood — factors influencing how a drug performs and how reliably it can be produced.

Polymorphism refers to the ability of a substance to exist in multiple crystalline forms that share the same chemical composition but differ in molecular arrangement. A classic example is carbon: materials like diamond, graphite, and fullerenes are all composed of the same element, yet exhibit dramatically different physical and chemical properties due to their distinct structures. The same principle applies to pharmaceutical compounds. APIs can exist in multiple polymorphic forms, each with unique characteristics that may impact solubility, stability, bioavailability, and manufacturability.

Polymorphs are just one category of solid forms. Others include solvates, hydrates, and amorphous materials. Solvates incorporate solvent molecules into their crystal structure, while hydrates specifically include water. Amorphous forms, by contrast, lack the ordered molecular structure of crystalline solids altogether. Many APIs can exist in multiple solid forms — sometimes just a few, but in some cases dozens — each presenting different development and manufacturing implications. Understanding and controlling these variations is essential to ensuring consistency, performance, and long-term success in drug development.